NASDAQ:AVDL - Avadel Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$6.42 -0.08 (-1.23 %)
(As of 05/24/2018 02:13 PM ET)
Previous Close$6.53
Today's Range$6.35 - $6.56
52-Week Range$6.17 - $11.93
Volume9,632 shs
Average Volume529,585 shs
Market Capitalization$246.19 million
P/E Ratio20.68
Dividend YieldN/A
Beta1.54

About Avadel Pharmaceuticals (NASDAQ:AVDL)

Avadel Pharmaceuticals logoAvadel Pharmaceuticals plc develops and commercializes pharmaceutical products primarily for treating urology and sleep medicines in the United States, France, and Ireland. Its commercial products that are used in the hospital setting include Bloxiverz, a drug used in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; Vazculep, a phenylephrine hydrochloride injection that is used for the treatment of hypotension occurring in the setting of anesthesia; and Akovaz, an ephedrine sulfate injection for treating hypotension, as well as Noctiva for treating nocturia due to nocturnal polyuria. The company owns and develops drug delivery platforms, such as Micropump, a microparticulate system that allows the development of modified and/or controlled release of solid and oral dosage formulations of drugs; LiquiTime, which allows development of modified/controlled release liquid suspension formulations; Trigger Lock that allows development of abuse-resistant modified/controlled release formulations of narcotic/opioid analgesics and other drugs susceptible to abuse; and Medusa, a hydrogel depot technology that allows the development of extended/modified release of injectable dosage formulations of drugs. Its product candidates also comprise REST-ON, which is in Phase III clinical trial for the treatment of daytime sleepiness and cataplexy in patients suffering from narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals PLC in January 2017. The company was founded in 1990 and is headquartered in Dublin, Ireland.

Receive AVDL News and Ratings via Email

Sign-up to receive the latest news and ratings for AVDL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AVDL
CUSIPN/A
Phone636-449-1830

Debt

Debt-to-Equity Ratio1.28
Current Ratio2.66
Quick Ratio2.59

Price-To-Earnings

Trailing P/E Ratio20.68
Forward P/E Ratio-4.14
P/E GrowthN/A

Sales & Book Value

Annual Sales$172.74 million
Price / Sales1.37
Cash Flow$0.4291 per share
Price / Cash14.96
Book Value$2.37 per share
Price / Book2.71

Profitability

EPS (Most Recent Fiscal Year)$0.31
Net Income$68.27 million
Net Margins18.96%
Return on Equity-13.95%
Return on Assets-4.22%

Miscellaneous

Employees180
Outstanding Shares36,740,000

Avadel Pharmaceuticals (NASDAQ:AVDL) Frequently Asked Questions

What is Avadel Pharmaceuticals' stock symbol?

Avadel Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVDL."

How will Avadel Pharmaceuticals' stock buyback program work?

Avadel Pharmaceuticals declared that its board has authorized a share buyback plan on Wednesday, March 28th 2018, which authorizes the company to repurchase $7,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to repurchase up to 2.7% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company's leadership believes its shares are undervalued.

How were Avadel Pharmaceuticals' earnings last quarter?

Avadel Pharmaceuticals (NASDAQ:AVDL) released its quarterly earnings results on Wednesday, May, 2nd. The company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.24) by $0.08. The company earned $33.29 million during the quarter, compared to analysts' expectations of $29.60 million. Avadel Pharmaceuticals had a net margin of 18.96% and a negative return on equity of 13.95%. View Avadel Pharmaceuticals' Earnings History.

When is Avadel Pharmaceuticals' next earnings date?

Avadel Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, August, 14th 2018. View Earnings Estimates for Avadel Pharmaceuticals.

What price target have analysts set for AVDL?

3 brokerages have issued twelve-month target prices for Avadel Pharmaceuticals' stock. Their forecasts range from $14.00 to $30.00. On average, they expect Avadel Pharmaceuticals' share price to reach $22.6667 in the next twelve months. View Analyst Ratings for Avadel Pharmaceuticals.

Who are some of Avadel Pharmaceuticals' key competitors?

Who are Avadel Pharmaceuticals' key executives?

Avadel Pharmaceuticals' management team includes the folowing people:
  • Mr. Michael S. Anderson, CEO & Director (Age 69)
  • Mr. Michael F. Kanan, CFO & Sr. VP (Age 55)
  • Mr. Phillandas T. Thompson J.D., M.B.A., Sr. VP, Gen. Counsel & Corp. Sec. (Age 44)
  • Ms. Sandra L. Hatten, Sr. VP of Quality & Regulatory Affairs (Age 61)
  • Dr. David Monteith Ph.D., VP of R&D (Age 54)

Has Avadel Pharmaceuticals been receiving favorable news coverage?

News coverage about AVDL stock has been trending somewhat positive recently, Accern reports. The research group ranks the sentiment of media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Avadel Pharmaceuticals earned a media sentiment score of 0.02 on Accern's scale. They also gave press coverage about the company an impact score of 43.77 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near term.

Who are Avadel Pharmaceuticals' major shareholders?

Avadel Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Millennium Management LLC (1.92%), BlackRock Inc. (1.28%), GSA Capital Partners LLP (0.79%), California Public Employees Retirement System (0.23%), Alps Advisors Inc. (0.13%) and Trexquant Investment LP (0.11%). Company insiders that own Avadel Pharmaceuticals stock include Craig R Stapleton, Francis Fildes, Greg J Divis, Guillaume Cerutti, Healthcare Master Fun Broadfin, Michael S Anderson, Peter J Thornton, Phillandas T Thompson and Sandra L Hatten. View Institutional Ownership Trends for Avadel Pharmaceuticals.

Which institutional investors are selling Avadel Pharmaceuticals stock?

AVDL stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC and BlackRock Inc.. Company insiders that have sold Avadel Pharmaceuticals company stock in the last year include Craig R Stapleton, Guillaume Cerutti and Healthcare Master Fun Broadfin. View Insider Buying and Selling for Avadel Pharmaceuticals.

Which institutional investors are buying Avadel Pharmaceuticals stock?

AVDL stock was bought by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP, Trexquant Investment LP, O Shaughnessy Asset Management LLC, Alps Advisors Inc. and California Public Employees Retirement System. Company insiders that have bought Avadel Pharmaceuticals stock in the last two years include Craig R Stapleton, Greg J Divis, Michael S Anderson, Peter J Thornton, Phillandas T Thompson and Sandra L Hatten. View Insider Buying and Selling for Avadel Pharmaceuticals.

How do I buy shares of Avadel Pharmaceuticals?

Shares of AVDL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Avadel Pharmaceuticals' stock price today?

One share of AVDL stock can currently be purchased for approximately $6.42.

How big of a company is Avadel Pharmaceuticals?

Avadel Pharmaceuticals has a market capitalization of $246.19 million and generates $172.74 million in revenue each year. The company earns $68.27 million in net income (profit) each year or $0.31 on an earnings per share basis. Avadel Pharmaceuticals employs 180 workers across the globe.

How can I contact Avadel Pharmaceuticals?

Avadel Pharmaceuticals' mailing address is BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK BALLYCOOLIN, DUBLIN L2, 63005. The company can be reached via phone at 636-449-1830 or via email at [email protected]


MarketBeat Community Rating for Avadel Pharmaceuticals (AVDL)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  183 (Vote Outperform)
Underperform Votes:  138 (Vote Underperform)
Total Votes:  321
MarketBeat's community ratings are surveys of what our community members think about Avadel Pharmaceuticals and other stocks. Vote "Outperform" if you believe AVDL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVDL will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Avadel Pharmaceuticals (NASDAQ:AVDL) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for Avadel Pharmaceuticals in the last 12 months. Their average twelve-month price target is $22.6667, suggesting that the stock has a possible upside of 253.06%. The high price target for AVDL is $30.00 and the low price target for AVDL is $14.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $22.6667$22.6667$24.6667$25.00
Price Target Upside: 253.06% upside210.93% upside171.96% upside179.02% upside

Avadel Pharmaceuticals (NASDAQ:AVDL) Consensus Price Target History

Price Target History for Avadel Pharmaceuticals (NASDAQ:AVDL)

Avadel Pharmaceuticals (NASDAQ:AVDL) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/9/2018Ladenburg ThalmannLower Price TargetBuy$24.00LowView Rating Details
1/3/2018Roth CapitalSet Price TargetBuy$14.00MediumView Rating Details
9/7/2017Langenberg & CompanyReiterated RatingBuy$27.00 ➝ $30.00LowView Rating Details
9/28/2016JMP SecuritiesReiterated RatingOutperform$16.00N/AView Rating Details
9/27/2016Leerink SwannReiterated RatingOutperform$16.00N/AView Rating Details
(Data available from 5/24/2016 forward)

Earnings

Avadel Pharmaceuticals (NASDAQ:AVDL) Earnings History and Estimates Chart

Earnings by Quarter for Avadel Pharmaceuticals (NASDAQ:AVDL)

Avadel Pharmaceuticals (NASDAQ:AVDL) Earnings Estimates

2018 EPS Consensus Estimate: ($1.39)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.17)($0.17)($0.17)
Q2 20181($0.37)($0.37)($0.37)
Q3 20181($0.41)($0.41)($0.41)
Q4 20181($0.44)($0.44)($0.44)

Avadel Pharmaceuticals (NASDAQ AVDL) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/14/2018        
5/2/20183/31/2018($0.24)($0.32)$29.60 million$33.29 millionViewN/AView Earnings Details
3/8/2018Before Market($0.23)($0.28)$34.16 million$34.20 millionViewListenView Earnings Details
11/8/2017Q3($0.04)$0.09$38.22 million$39.68 millionViewN/AView Earnings Details
8/8/20176/30/2017$0.05$0.19$45.17 million$46.30 millionViewListenView Earnings Details
5/9/20173/31/2017$0.07$0.26$46.01 million$52.50 millionViewListenView Earnings Details
3/7/201712/31/2016($0.03)$0.26$34.72 million$43.09 millionViewListenView Earnings Details
11/7/2016Q316($0.07)($0.08)$30.70 million$32.10 millionViewListenView Earnings Details
8/8/2016Q216$0.06($0.02)$32.80 million$38.90 millionViewN/AView Earnings Details
5/9/2016Q116$0.14$0.04$34.00 million$36.20 millionViewN/AView Earnings Details
3/10/2016Q415$0.09$0.32$44.69 million$43.40 millionViewListenView Earnings Details
11/12/2015Q215$0.23$0.28$50.33 million$47.30 millionViewListenView Earnings Details
7/30/2015Q2$0.40$0.34$62.50 million$49.80 millionViewListenView Earnings Details
5/15/2015Q115$0.18$0.34$37.37 million$32.73 millionViewListenView Earnings Details
3/19/2015Q414($0.22)($0.12)$13.10 million$3.00 millionViewN/AView Earnings Details
10/31/2014Q3 14($0.12)($0.16)$12.00 million$7.00 millionViewN/AView Earnings Details
7/29/2014Q214($0.08)($0.13)$9.92 million$8.10 millionViewN/AView Earnings Details
5/12/2014Q1 14($0.15)($0.15)$7.47 million$9.20 millionViewN/AView Earnings Details
3/11/2014Q4 2013($0.26)$0.20$5.74 million$6.18 millionViewN/AView Earnings Details
10/31/2013Q313($0.20)($0.25)$6.47 million$5.60 millionViewN/AView Earnings Details
7/29/2013Q2 2013($0.27)($0.09)$5.35 million$5.50 millionViewN/AView Earnings Details
5/7/2013Q1 2013($0.33)($0.23)$6.11 million$5.10 millionViewN/AView Earnings Details
2/28/2013Q4 2012($0.19)($0.14)ViewN/AView Earnings Details
11/5/2012Q312($0.19)($0.26)$6.35 million$5.40 millionViewN/AView Earnings Details
7/25/2012Q2 2012($0.08)($0.25)ViewN/AView Earnings Details
5/7/2012Q1 2012($0.07)($0.19)ViewN/AView Earnings Details
3/14/2012Q4 2011$0.10($0.08)ViewN/AView Earnings Details
11/2/2011Q3 2011($0.09)$0.07ViewN/AView Earnings Details
7/25/2011Q2 2011($0.09)($0.14)ViewN/AView Earnings Details
5/9/2011Q1 2011($0.11)($0.20)ViewN/AView Earnings Details
3/3/2011Q4 2010$0.05$0.11ViewN/AView Earnings Details
11/4/2010Q3 2010($0.14)ViewN/AView Earnings Details
7/28/2010Q2 2010($0.05)($0.18)ViewN/AView Earnings Details
5/5/2010Q1 2010($0.13)($0.17)ViewN/AView Earnings Details
3/8/2010Q4 2009($0.10)($0.24)ViewN/AView Earnings Details
11/16/2009Q3 2009($0.09)($0.14)ViewN/AView Earnings Details
8/5/2009Q2 2009($0.10)($0.15)ViewN/AView Earnings Details
5/11/2009Q1 2009($0.14)$0.05ViewN/AView Earnings Details
3/4/2009Q4 2008($0.02)($0.11)ViewN/AView Earnings Details
11/3/2008Q3 2008($0.17)($0.10)ViewN/AView Earnings Details
8/6/2008Q2 2008($0.25)($0.14)ViewN/AView Earnings Details
5/13/2008Q1 2008($0.15)ViewN/AView Earnings Details
3/3/2008Q4 2007($0.30)($0.23)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Avadel Pharmaceuticals (NASDAQ:AVDL) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Avadel Pharmaceuticals (NASDAQ AVDL) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.31%
Institutional Ownership Percentage: 69.55%
Insider Trading History for Avadel Pharmaceuticals (NASDAQ:AVDL)
Institutional Ownership by Quarter for Avadel Pharmaceuticals (NASDAQ:AVDL)

Avadel Pharmaceuticals (NASDAQ AVDL) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/15/2017Craig R StapletonDirectorBuy140,000$8.67$1,213,800.00View SEC Filing  
12/7/2017Michael S. AndersonCEOBuy5,000$8.86$44,300.00View SEC Filing  
11/27/2017Craig R StapletonDirectorSell254,265$9.35$2,377,377.75253,413View SEC Filing  
9/21/2017Peter J ThorntonDirectorBuy5,155$9.74$50,209.705,155View SEC Filing  
9/14/2017Sandra L. HattenInsiderBuy2,100$9.36$19,656.00View SEC Filing  
9/13/2017Phillandas T. ThompsonInsiderBuy5,000$9.36$46,800.00View SEC Filing  
9/12/2017Craig R StapletonDirectorBuy20,000$9.52$190,400.00507,678View SEC Filing  
9/12/2017Greg J DivisInsiderBuy10,600$9.32$98,792.0010,600View SEC Filing  
9/12/2017Michael S. AndersonCEOBuy4,000$9.80$39,200.00View SEC Filing  
6/23/2017Healthcare Master Fun BroadfinMajor ShareholderSell261,000$10.68$2,787,480.00View SEC Filing  
6/15/2017Guillaume CeruttiDirectorSell26,560$10.46$277,817.6023,440View SEC Filing  
5/22/2017Craig R StapletonDirectorBuy31,013$9.85$305,478.05507,678View SEC Filing  
5/19/2017Michael S AndersonCEOBuy2,500$10.00$25,000.00225,750View SEC Filing  
11/29/2016Craig R StapletonDirectorBuy20,000$10.79$215,800.00519,678View SEC Filing  
11/21/2016Michael S. AndersonCEOBuy2,000$10.64$21,280.00View SEC Filing  
9/22/2016Francis FildesDirectorSell15,000$13.45$201,750.0015,000View SEC Filing  
9/2/2016Michael S. AndersonCEOBuy2,000$14.12$28,240.00View SEC Filing  
9/1/2016Craig R StapletonDirectorBuy10,000$13.52$135,200.00519,678View SEC Filing  
8/26/2016Craig R StapletonDirectorBuy20,000$13.76$275,200.00509,678View SEC Filing  
8/22/2016Michael S. AndersonCEOBuy5,000$14.30$71,500.00View SEC Filing  
5/16/2016Craig R StapletonDirectorBuy27,228$9.21$250,769.88507,263View SEC Filing  
5/12/2016Michael S AndersonCEOBuy5,000$8.84$44,200.00134,250View SEC Filing  
3/22/2016Phillandas T ThompsonInsiderBuy10,000$11.10$111,000.0020,000View SEC Filing  
3/18/2016Michael S AndersonCEOBuy5,000$11.04$55,200.00129,250View SEC Filing  
3/18/2016Sandra L HattenVPBuy3,000$11.01$33,030.003,000View SEC Filing  
3/14/2016Craig R StapletonDirectorBuy100,000$10.39$1,039,000.00482,450View SEC Filing  
3/14/2016Michael S AndersonInsiderBuy10,000$9.74$97,400.00124,250View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Avadel Pharmaceuticals (NASDAQ AVDL) News Headlines

Source:
DateHeadline
Avadel Pharmaceuticals (AVDL) Receives Average Recommendation of "Hold" from AnalystsAvadel Pharmaceuticals (AVDL) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - May 23 at 3:36 AM
Avadel Pharmaceuticals (AVDL) Upgraded to Sell at BidaskClubAvadel Pharmaceuticals (AVDL) Upgraded to Sell at BidaskClub
www.americanbankingnews.com - May 18 at 5:13 PM
Avadel to Present Late-Breaker Data and Product Theater Forum at the 2018 American Urological Association Annual MeetingAvadel to Present Late-Breaker Data and Product Theater Forum at the 2018 American Urological Association Annual Meeting
finance.yahoo.com - May 18 at 11:13 AM
Analyzing Avadel Pharmaceuticals (AVDL) and Its RivalsAnalyzing Avadel Pharmaceuticals (AVDL) and Its Rivals
www.americanbankingnews.com - May 14 at 5:16 PM
Avadel Pharmaceuticals (AVDL) Rating Lowered to Strong Sell at BidaskClubAvadel Pharmaceuticals (AVDL) Rating Lowered to Strong Sell at BidaskClub
www.americanbankingnews.com - May 11 at 9:13 PM
Research Analysts Offer Predictions for Avadel Pharmaceuticals Q2 2018 Earnings (AVDL)Research Analysts Offer Predictions for Avadel Pharmaceuticals' Q2 2018 Earnings (AVDL)
www.americanbankingnews.com - May 7 at 2:46 AM
Avadel Pharmaceuticals (AVDL) Issues Quarterly  Earnings Results, Misses Estimates By $0.08 EPSAvadel Pharmaceuticals (AVDL) Issues Quarterly Earnings Results, Misses Estimates By $0.08 EPS
www.americanbankingnews.com - May 3 at 2:54 PM
Avadel Pharmaceuticals (AVDL) CEO Michael Anderson On Q1 2018 Results - Earnings Call TranscriptAvadel Pharmaceuticals' (AVDL) CEO Michael Anderson On Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 3 at 9:47 AM
Equities Analysts Issue Forecasts for Avadel Pharmaceuticals Q1 2018 Earnings (AVDL)Equities Analysts Issue Forecasts for Avadel Pharmaceuticals' Q1 2018 Earnings (AVDL)
www.americanbankingnews.com - May 3 at 7:50 AM
Avadel Pharmaceuticals beats by $0.03, beats on revenueAvadel Pharmaceuticals beats by $0.03, beats on revenue
seekingalpha.com - May 2 at 9:51 AM
Avadel: 1Q Earnings SnapshotAvadel: 1Q Earnings Snapshot
finance.yahoo.com - May 2 at 9:50 AM
Avadel Pharmaceuticals Reports First Quarter 2018 ResultsAvadel Pharmaceuticals Reports First Quarter 2018 Results
finance.yahoo.com - May 2 at 9:50 AM
Avadel Pharmaceuticals (AVDL) Cut to "Sell" at ValuEngineAvadel Pharmaceuticals (AVDL) Cut to "Sell" at ValuEngine
www.americanbankingnews.com - May 1 at 11:18 AM
Avadel Launches NOCTIVA™, the First and Only FDA-Approved Treatment for Nocturia Due to Nocturnal PolyuriaAvadel Launches NOCTIVA™, the First and Only FDA-Approved Treatment for Nocturia Due to Nocturnal Polyuria
finance.yahoo.com - May 1 at 9:51 AM
Avadel Pharmaceuticals to Present at the Deutsche Bank 43rd Annual Health Care ConferenceAvadel Pharmaceuticals to Present at the Deutsche Bank 43rd Annual Health Care Conference
finance.yahoo.com - April 30 at 4:07 PM
Avadel Pharmaceuticals (AVDL) Receives Consensus Recommendation of "Hold" from BrokeragesAvadel Pharmaceuticals (AVDL) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - April 28 at 3:37 AM
Avadel Pharmaceuticals to Report First Quarter 2018 ResultsAvadel Pharmaceuticals to Report First Quarter 2018 Results
finance.yahoo.com - April 24 at 9:56 AM
Avadel Pharmaceuticals (AVDL) Lowered to Sell at BidaskClubAvadel Pharmaceuticals (AVDL) Lowered to Sell at BidaskClub
www.americanbankingnews.com - April 21 at 7:06 AM
Avadel Pharmaceuticals plc (NASDAQ:AVDL): What’s The Analyst Consensus Outlook?Avadel Pharmaceuticals plc (NASDAQ:AVDL): What’s The Analyst Consensus Outlook?
finance.yahoo.com - April 17 at 4:13 PM
Avadel Pharmaceuticals (AVDL) Given a $15.00 Price Target at Roth CapitalAvadel Pharmaceuticals (AVDL) Given a $15.00 Price Target at Roth Capital
www.americanbankingnews.com - April 11 at 12:43 AM
Detailed Research: Economic Perspectives on VASCO Data Security International ...Detailed Research: Economic Perspectives on VASCO Data Security International ...
globenewswire.com - April 6 at 10:38 AM
Avadel Offers An Excellent Risk/Reward ProfileAvadel Offers An Excellent Risk/Reward Profile
seekingalpha.com - April 4 at 5:35 PM
Avadel Pharmaceuticals (AVDL) Upgraded to Hold at BidaskClubAvadel Pharmaceuticals (AVDL) Upgraded to Hold at BidaskClub
www.americanbankingnews.com - April 4 at 9:55 AM
Avadel Pharmaceuticals (AVDL) Stock Rating Upgraded by ValuEngineAvadel Pharmaceuticals (AVDL) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - April 3 at 6:59 PM
Avadel Pharma (AVDL) Announces Acceptance of Late-Breaker Presentation for NOCTIVA at AUAAvadel Pharma (AVDL) Announces Acceptance of Late-Breaker Presentation for NOCTIVA at AUA
www.streetinsider.com - April 3 at 10:18 AM
Avadel Pharmaceuticals (AVDL) Given Average Rating of "Hold" by BrokeragesAvadel Pharmaceuticals (AVDL) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - April 3 at 3:08 AM
Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL) Rating Increased to Sell at BidaskClubAvadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL) Rating Increased to Sell at BidaskClub
www.americanbankingnews.com - March 30 at 6:14 PM
Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL) Stock Rating Upgraded by BidaskClubAvadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - March 29 at 6:54 PM
Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL) to Buyback $7.00 million in   Stock Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL) to Buyback $7.00 million in Stock
www.americanbankingnews.com - March 28 at 11:20 AM
Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL) Raised to Buy at BidaskClubAvadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL) Raised to Buy at BidaskClub
www.americanbankingnews.com - March 26 at 11:30 PM
Avadel Pharmaceuticals Announces Promotion of Gregory J. Divis to Chief Operating OfficerAvadel Pharmaceuticals Announces Promotion of Gregory J. Divis to Chief Operating Officer
finance.yahoo.com - March 22 at 9:52 AM
Jazz Pharma Upgraded On Bullish Pipeline Forecast, Earnings Growth Visibility, M&A PotentialJazz Pharma Upgraded On Bullish Pipeline Forecast, Earnings Growth Visibility, M&A Potential
finance.yahoo.com - March 19 at 4:13 PM
Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL) Downgraded by BidaskClub to SellAvadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL) Downgraded by BidaskClub to Sell
www.americanbankingnews.com - March 18 at 7:10 PM
Analysts Offer Predictions for Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Shares FY2022 Earnings (AVDL)Analysts Offer Predictions for Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share's FY2022 Earnings (AVDL)
www.americanbankingnews.com - March 12 at 10:41 AM
Short Interest in Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL) Grows By 344.3%Short Interest in Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL) Grows By 344.3%
www.americanbankingnews.com - March 11 at 1:16 AM
Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL) Rating Lowered to Sell at ValuEngineAvadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL) Rating Lowered to Sell at ValuEngine
www.americanbankingnews.com - March 10 at 8:16 PM
Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL) Stock Rating Lowered by TheStreetAvadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL) Stock Rating Lowered by TheStreet
www.americanbankingnews.com - March 10 at 12:04 PM
Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL) Given Average Rating of "Hold" by AnalystsAvadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - March 9 at 9:36 PM
Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL) Price Target Lowered to $24.00 at Ladenburg Thalmann Financial ServicesAvadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL) Price Target Lowered to $24.00 at Ladenburg Thalmann Financial Services
www.americanbankingnews.com - March 9 at 8:33 PM
Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL) Stock Rating Upgraded by Zacks Investment ResearchAvadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - March 9 at 6:48 PM
SunTrust Banks Analysts Boost Earnings Estimates for Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL)SunTrust Banks Analysts Boost Earnings Estimates for Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL)
www.americanbankingnews.com - March 9 at 8:52 AM
Avadel Pharmaceuticals Reports Fourth Quarter and Full Year 2017 ResultsAvadel Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Results
finance.yahoo.com - March 8 at 11:17 AM
Avadel reports 4Q lossAvadel reports 4Q loss
finance.yahoo.com - March 8 at 11:17 AM
Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL) Posts Quarterly  Earnings Results, Misses Expectations By $0.01 EPSAvadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL) Posts Quarterly Earnings Results, Misses Expectations By $0.01 EPS
www.americanbankingnews.com - March 8 at 9:58 AM
Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL) Upgraded by BidaskClub to HoldAvadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL) Upgraded by BidaskClub to Hold
www.americanbankingnews.com - March 4 at 12:16 AM
Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL) Expected to Announce Quarterly Sales of $29.79 MillionAvadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL) Expected to Announce Quarterly Sales of $29.79 Million
www.americanbankingnews.com - March 3 at 3:08 PM
Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL) Scheduled to Post Earnings on ThursdayAvadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL) Scheduled to Post Earnings on Thursday
www.americanbankingnews.com - March 1 at 2:08 AM
Avadel Pharmaceuticals to Report Fourth Quarter and Full Year 2017 ResultsAvadel Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Results
finance.yahoo.com - February 26 at 10:12 AM
Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL) Rating Lowered to Sell at BidaskClubAvadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL) Rating Lowered to Sell at BidaskClub
www.americanbankingnews.com - February 17 at 11:36 PM
Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL) Lowered to Sell at Zacks Investment ResearchAvadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL) Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - February 16 at 6:02 PM

SEC Filings

Avadel Pharmaceuticals (NASDAQ:AVDL) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Avadel Pharmaceuticals (NASDAQ:AVDL) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Avadel Pharmaceuticals (NASDAQ AVDL) Stock Chart for Thursday, May, 24, 2018

Loading chart…

This page was last updated on 5/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.